4O First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes - Valdiviezo, N; Okamoto, I; Hughes, B GM (ESMO Open, 2024)